Skip to main content

MedCloud Minute

Blog archive

GC Biopharma Advances IVIG Safety with New Impurity Detection Technology

Key Takeaways

  • GC Biopharma develops assay to detect prothrombotic impurities in IVIG therapies.
  • Selective IgG blocker improves precision in measuring clotting risk factors during production.
  • Advanced quality control enhances IVIG safety and reduces thrombotic adverse event risks.

GC Biopharma, a biopharmaceutical company focused on manufacturing plasma derivatives, announced a new technology designed to improve the safety profile of intravenous immunoglobulin (IVIG) therapies by detecting prothrombotic impurities. The method enhances its ability to identify trace impurities that may increase the risk of blood clotting in patients receiving IVIG treatments. These therapies are widely used to treat immune deficiencies and autoimmune conditions, making safety a critical concern in manufacturing and quality control. The enhanced assay incorporates a selective IgG Blocker, suppressing non-specific protein reactions ensuring a precise measurement of FXI regardless of the IgG concentration.

GC Biopharma said the detection technology is intended to strengthen product consistency and reduce potential adverse effects associated with thrombotic events. The approach focuses on improving analytical precision during the production process. Biopharmaceutical manufacturers are increasingly investing in advanced quality control technologies to meet regulatory standards and ensure patient safety.

Posted by MedCloudInsider Editors on 04/06/2026